(MENAFN- GetNews)
DelveInsight's,
“Gastric Cancer Pipeline Insight 2024”
report provides comprehensive insights about
180+ companies and 200+ pipeline drugs
in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including Gastric Cancer clinical trials and nonclinical stage products. It also covers the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Gastric Cancer Pipeline Report
DelveInsight's Gastric Cancer pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Gastric Cancer treatment. The leading Gastric Cancer Companies working in the market include Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, Taiho Oncology, Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co., Ltd, Shanghai Miracogen Inc., RemeGen Co., Ltd., Idience Co., Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co. Ltd., MacroGenics, Sichuan Baili Pharmaceutical Co., Ltd., LianBio LLC, and Janssen Pharmaceutical, and others. Promising Gastric Cancer Therapies in the various stages of development include Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022,
TCRx_T Cells,
IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410,
PT 886, PRS-343, Oraxol, CA-4948,
Q702,
ACE1702, SI-B001, TT-4, LUM015,
LB 1908, CUE-102,
TORL-2-307-MAB,
OBI-833/OBI-821,
ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110,
LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453,
CCT303-406, VMD-928,
ITI 4000, PAb 001, and others. April 2024: Singlera Genomics Inc-The objective is to explore the clinical performance of polygene methylation (PCR-fluorescence probe) in the adjunctive diagnosis of gastric cancer, including the sensitivity of detection of various types and stages of gastric cancer, the specificity of detection of healthy controls, precancerous states, precancerous lesions, and the detection interference of other cancers. The diagnostic performance will be compared with CA199, CEA and CA724. The research data will provide a basis for screening targets for the development of detection kits. March 2024:- Vivian Wing Yan Lee- This is a retrospective cost-minimization analysis study to compare the costs of treatment with EOF vs EOX regimens in patients with gastric cancer (GC) in Hong Kong. Patient baseline characteristics and cost data will be extracted from records and compared. The oral chemotherapy agent Xeloda® was recently extended by the Hong Kong Hospital Authority as subsidized therapy for the treatment of colorectal cancer1. February 2024:- Bristol-Myers Squibb- The purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic gastric or GEJ cancer. A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma. February 2024:- Ambrx Inc.- A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression. This 2-part, Phase 1, open-label study will determine the recommended Phase 2 dose (RP2D) of ARX788 in subjects with advanced HER2 positive cancers and will assess the safety and anticancer activity in breast, gastric and other advanced HER2 positive solid tumors.
Request a sample and discover the recent advances in Gastric Cancer @ Gastric Cancer Pipeline Outlook Report
Gastric Cancer Overview
Stomach cancer is cancer that starts anywhere inside the stomach or the stomach wall. It's also called gastric cancer. Stomach cancer is more common in older people. Around 50 out of 100 cases (around 50%) occur in people aged 75 or over. It is more common in men than women. About 95% of the time, stomach cancer starts in the stomach lining and progresses slowly. Many stomach cancers are linked to lifestyle or environmental factors, including diet. Stomach cancer is linked with a bacteria that lives in the stomach called Helicobacter pylori. But not everyone with Helicobacter pylori will develop stomach cancer.
Gastric Cancer Emerging Drugs Profile
Catumaxomab: Linton Pharm Co. Ltd. HLX10: Shanghai Henlius Biotech FLX475: RAPT Therapeutics Savolitinib: AstraZeneca/HUTCHMED ASP 2138: Astellas Pharma Minnelide : Minneamrita Therapeutics LLC
Learn more about the Gastric Cancer in clinical trials @ Gastric Cancer Drugs
Gastric Cancer Therapeutics Assessment
There are approx. 180+ Gastric Cancer companies which are developing the Gastric Cancer therapies. The Gastric Cancer companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Linton Pharm Co. Ltd.
DelveInsight's Gastric Cancer pipeline report covers around 200+ products under different phases of clinical development like
Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates
Discover more about Gastric Cancer in development @ Gastric Cancer Clinical Trials
Gastric Cancer Companies
Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, Taiho Oncology, Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co., Ltd, Shanghai Miracogen Inc., RemeGen Co., Ltd., Idience Co., Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co. Ltd., MacroGenics, Sichuan Baili Pharmaceutical Co., Ltd., LianBio LLC, and Janssen Pharmaceutical, and others.
Gastric Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral Parenteral Intravenous Subcutaneous Topical. Molecule Type
Gastric Cancer Products have been categorized under various Molecule types such as
Monoclonal Antibody Peptides Polymer Small molecule Gene therapy
To learn more about Gastric Cancer, visit @ Gastric Cancer Segmentation
Scope of the Gastric Cancer Pipeline Report
Coverage- Global Gastric Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Gastric Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Gastric Cancer Companies- Linton Pharm Co. Ltd., Shanghai Henlius Biotech, RAPT Therapeutics, AstraZeneca, Astellas Pharma, Minneamrita Therapeutics, Aston Science, Servier Bio-Innovation LLC, Bukwang Pharmaceutical, Taiho Oncology, Inc., Novartis Pharmaceuticals, Base Therapeutics (Shanghai) Co., Ltd, Shanghai Miracogen Inc., RemeGen Co., Ltd., Idience Co., Ltd., BeiGene, Ono Pharmaceutical Co. Ltd, Elevar Therapeutics, R-Pharm, Innovent Biologics (Suzhou) Co. Ltd., MacroGenics, Sichuan Baili Pharmaceutical Co., Ltd., LianBio LLC, and Janssen Pharmaceutical, and others. Gastric Cancer Therapies- Avelumab, BBI608, Camrelizumab, Catumaxomab, RAPA-201, SHR-1210, Amivantamab, Atezolizumab, Bevacizumab, Cabozantinib, Cinrebafusp alfa, Crizotinib, DKN-01, DP303c, Eflornithine, EP0057, Epacadostat, FLX475, Futibatinib, GEN-001, HLX07, HLX22, Infigratinib, KH903, Lenvatinib, Masitinib, MAX-40279, MRG002, MRG003, Niraparib, Savolitinib, Minnelide, SHR-1701, Margetuximab, Bemarituzumab, Evorpacept, Lenvatinib, CDK-004, TPX-0022,
TCRx_T Cells,
IN10018, IMU-131, SOT102, CT041, AB011, Zanidatamab, NC410,
PT 886, PRS-343, Oraxol, CA-4948,
Q702,
ACE1702, SI-B001, TT-4, LUM015,
LB 1908, CUE-102,
TORL-2-307-MAB,
OBI-833/OBI-821,
ASP2138, NC410, SO-C101, HC-5404-FU, CPL304110,
LNS8801, RGX-202-01, A166, GZ17-6.02, HMPL-453,
CCT303-406, VMD-928,
ITI 4000, PAb 001, and others.
For further information on the Gastric Cancer pipeline therapeutics, reach out @ Gastric Cancer Products Development
Table of Content
Introduction
Executive Summary
Gastric Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Comparative Analysis
Catumaxomab : Neovii Biotech
Drug profiles in the detailed report.....
Mid Stage Products (Phase II)
FLX475: RAPT Therapeutics
Early Stage Products (Phase I)
Comparative Analysis
ASP 2138: Astellas Pharma
Inactive Products
Gastric Cancer Key Companies
Gastric Cancer Key Products
Gastric Cancer - Unmet Needs
Gastric Cancer - Market Drivers and Barriers
Gastric Cancer - Future Perspectives and Conclusion
Gastric Cancer Analyst Views
Gastric Cancer Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
MENAFN06052024003238003268ID1108180411
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.